Takuo Ogihara

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/94376/publications.pdf Version: 2024-02-01



ΤΛΚΙΙΟ ΟΟΙΗΛΡΑ

| # | Article | IF | CITATIONS |
|----|---|-----|-----------|
| 1 | Effect of metformin on ¹⁸ F-fluorodeoxyglucose uptake and positron emission tomographic imaging. British Journal of Radiology, 2022, 95, 20200810. | 2.2 | 5 |
| 2 | Directional Drug Transport through Membrane-Supported Monolayers of Human Liver-Derived Cell Lines. Biological and Pharmaceutical Bulletin, 2022, 45, 150-153. | 1.4 | 1 |
| 3 | Slug Mediates MRP2 Expression in Non-Small Cell Lung Cancer Cells. Biomolecules, 2022, 12, 806. | 4.0 | 2 |
| 4 | Functional Alterations of Multidrug Resistance-Associated Proteins 2 and 5, and Breast Cancer Resistance Protein upon Snail-Induced Epithelial–Mesenchymal Transition in HCC827 Cells. Biological and Pharmaceutical Bulletin, 2021, 44, 103-111. | 1.4 | 5 |
| 5 | Correlations of mRNA Levels among Efflux Transporters, Transcriptional Regulators, and Scaffold Proteins in Non-Small-Cell Lung Cancer. Canadian Journal of Infectious Diseases and Medical Microbiology, 2021, 2021, 1-6. | 1.9 | 1 |
| 6 | Imaging modalities for monitoring acute therapeutic effects after nearâ€infrared photoimmunotherapy in vivo. Journal of Biophotonics, 2021, 15, e202100266. | 2.3 | 3 |
| 7 | Structure-activity relationship of atorvastatin derivatives for metabolic activation by hydrolases. Xenobiotica, 2020, 50, 261-269. | 1.1 | 11 |
| 8 | Establishment of a primary human hepatocyte spheroid system for evaluating metabolic toxicity using dacarbazine under conditions of CYP1A2 induction. Drug Metabolism and Pharmacokinetics, 2020, 35, 201-206. | 2.2 | 12 |
| 9 | Utility of Three-Dimensional Cultures of Primary Human Hepatocytes (Spheroids) as Pharmacokinetic Models. Biomedicines, 2020, 8, 374. | 3.2 | 19 |
| 10 | Moesin-Mediated P-Glycoprotein Activation During Snail-Induced Epithelial-Mesenchymal Transition in Lung Cancer Cells. Journal of Pharmaceutical Sciences, 2020, 109, 2302-2308. | 3.3 | 15 |
| 11 | Possible utility of peptide-transporter-targeting [19F]dipeptides for visualization of the biodistribution of cancers by nuclear magnetic resonance imaging. International Journal of Pharmaceutics, 2020, 586, 119575. | 5.2 | 0 |
| 12 | Physiological Roles of ERM Proteins and Transcriptional Regulators in Supporting Membrane Expression of Efflux Transporters as Factors of Drug Resistance in Cancer. Cancers, 2020, 12, 3352. | 3.7 | 25 |
| 13 | Regulation of breast cancer resistance protein and P-glycoprotein by ezrin, radixin and moesin in lung, intestinal and renal cancer cell lines. Journal of Pharmacy and Pharmacology, 2020, 72, 575-582. | 2.4 | 22 |
| 14 | Gastrointestinal absorption of pimozide is enhanced by inhibition of P-glycoprotein. PLoS ONE, 2020, 15, e0232438. | 2.5 | 7 |
| 15 | Usefulness and limitations of mRNA measurement in HepaRG cells for evaluation of cytochrome P450 induction. Fundamental Toxicological Sciences, 2020, 7, 9-14. | 0.6 | 3 |
| 16 | Testosterone and androstenedione are endogenous substrates of P-glycoprotein. Biochemical and Biophysical Research Communications, 2019, 520, 166-170. | 2.1 | 15 |
| 17 | Reduction Effect of Calcium Alginate on Blood Triglyceride Levels Causing the Inhibition of Hepatic and Total Body Accumulation of Fat in Rats. Biological and Pharmaceutical Bulletin, 2019, 42, 365-372. | 1.4 | 7 |
| 18 | Evaluation of the metabolic capability of primary human hepatocytes in threeâ€dimensional cultures on microstructural plates. Biopharmaceutics and Drug Disposition, 2018, 39, 187-195. | 1.9 | 8 |

TAKUO OGIHARA

| # | Article | IF | CITATIONS |
|----|--|-----|-----------|
| 19 | Advances in Studies of P-Glycoprotein and Its Expression Regulators. Biological and Pharmaceutical Bulletin, 2018, 41, 11-19. | 1.4 | 29 |
| 20 | Combination Metabolomics Approach for Identifying Endogenous Substrates of Carnitine/Organic Cation Transporter OCTN1. Pharmaceutical Research, 2018, 35, 224. | 3.5 | 11 |
| 21 | Randomized, Double-Blind, Crossover Clinical Trial of the Effect of Calcium Alginate in Noodles on Postprandial Blood Glucose Level. Biological and Pharmaceutical Bulletin, 2018, 41, 1367-1371. | 1.4 | 10 |
| 22 | Intestinal secretion of indoxyl sulfate as a possible compensatory excretion pathway in chronic kidney disease. Biopharmaceutics and Drug Disposition, 2018, 39, 328-334. | 1.9 | 9 |
| 23 | Entinostat reverses P-glycoprotein activation in snail-overexpressing adenocarcinoma HCC827 cells. PLoS ONE, 2018, 13, e0200015. | 2.5 | 9 |
| 24 | Mechanism of Suppression of Blood Glucose Level by Calcium Alginate in Rats. Biological and Pharmaceutical Bulletin, 2018, 41, 1362-1366. | 1.4 | 13 |
| 25 | Snail-Induced Epithelial-to-Mesenchymal Transition Enhances P-gp-Mediated Multidrug Resistance in HCC827 Cells. Journal of Pharmaceutical Sciences, 2017, 106, 2642-2649. | 3.3 | 30 |
| 26 | Preliminary Evaluation of Three-Dimensional Primary Human Hepatocyte Culture System for Assay of Drug-Metabolizing Enzyme-Inducing Potential. Biological and Pharmaceutical Bulletin, 2017, 40, 967-974. | 1.4 | 20 |
| 27 | Utility of human hepatocyte spheroids without feeder cells for evaluation of hepatotoxicity. Journal of Toxicological Sciences, 2017, 42, 499-507. | 1.5 | 18 |
| 28 | Different regulation of P-glycoprotein function between Caco-2 and Caki-1 cells by ezrin, radixin and moesin proteins. Journal of Pharmacy and Pharmacology, 2016, 68, 361-367. | 2.4 | 21 |
| 29 | Adenovirus vector infection of non-small-cell lung cancer cells is a trigger for multi-drug resistance mediated by P-glycoprotein. Biochemical and Biophysical Research Communications, 2016, 476, 183-187. | 2.1 | 5 |
| 30 | Possible interaction of quinolone antibiotics with peptide transporter 1 in oral absorption of peptideâ€mimetic drugs. Biopharmaceutics and Drug Disposition, 2016, 37, 39-45. | 1.9 | 3 |
| 31 | Interaction of Peptide Transporter 1 With d-Glucose and l-Glutamic Acid; Possible Involvement of Taste Receptors. Journal of Pharmaceutical Sciences, 2016, 105, 339-342. | 3.3 | 6 |
| 32 | Comparison of Brand-name and Generic Products of Latanoprost Ophthalmic Solution with Respect to the Sense of Use. Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences), 2016, 42, 651-658. | 0.1 | 2 |
| 33 | Utility of human hepatocyte spheroids for evaluation of hepatotoxicity. Fundamental Toxicological Sciences, 2015, 2, 41-48. | 0.6 | 11 |
| 34 | Pharmacokinetics of ethyl eicosapentaenoate (EPA-E). Journal of Lipid Nutrition, 2015, 24, 21-32. | 0.1 | 0 |
| 35 | Multiple Linear Regression Analysis Indicates Association of P-Glycoprotein Substrate or Inhibitor Character with Bitterness Intensity Measured with a Sensor. Journal of Pharmaceutical Sciences, 2015, 104, 2789-2794. | 3.3 | 3 |
| 36 | Analysis of a child who developed abnormal neuropsychiatric symptoms after administration of oseltamivir: a case report. BMC Neurology, 2015, 15, 130. | 1.8 | 15 |

TAKUO OGIHARA

| # | Article | IF | CITATIONS |
|----|--|-----------|--------------|
| 37 | Luteolin and Quercetin Affect the Cholesterol Absorption Mediated by Epithelial Cholesterol Transporter Niemann–Pick C1-Like 1 in Caco-2 Cells and Rats. PLoS ONE, 2014, 9, e97901. | 2.5 | 73 |
| 38 | Evaluation of Human Hepatocytes Cultured by Three-dimensional Spheroid Systems for Drug Metabolism. Drug Metabolism and Pharmacokinetics, 2014, 29, 373-378. | 2.2 | 58 |
| 39 | Evaluation of a Thiodipeptide, l-Phenylalanyl-Î [CS-N]-l-alanine, as a Novel Probe for Peptide Transporter 1. Drug Metabolism and Pharmacokinetics, 2014, 29, 470-474. | 2.2 | 4 |
| 40 | Role of P-Glycoprotein in Regulating Cilnidipine Distribution to Intact and Ischemic Brain. Drug Metabolism and Pharmacokinetics, 2014, 29, 254-258. | 2.2 | 17 |
| 41 | Stability of the Oral Formulation in No Packaging State. Iryo Yakugaku (Japanese Journal of) Tj ETQq1 1 0.784314 | rgBT /Ove | erlock 10 Tf |
| 42 | Contribution of Radixin to P-Glycoprotein Expression and Transport Activity in Mouse Small Intestine In Vivo. Journal of Pharmaceutical Sciences, 2013, 102, 2875-2881. | 3.3 | 28 |
| 43 | Foreword. Biological and Pharmaceutical Bulletin, 2013, 36, 691-691. | 1.4 | 2 |
| 44 | Clinical impact and evidence of pharmacokinetic change by genetic polymorphism. Drug Metabolism and Pharmacokinetics, 2013, 28, 3. | 2.2 | 0 |
| 45 | Developmental changes of brain distribution and localization of oseltamivir and its active metabolite Ro 64-0802 in rats. Journal of Toxicological Sciences, 2012, 37, 1217-1223. | 1.5 | 8 |
| 46 | Effect of Knockdown of Ezrin, Radixin, and Moesin on P-Glycoprotein Function in HepG2 Cells. Journal of Pharmaceutical Sciences, 2011, 100, 5308-5314. | 3.3 | 43 |
| 47 | Oseltamivir (Tamiflu) Is a Substrate of Peptide Transporter 1. Drug Metabolism and Disposition, 2009, 37, 1676-1681. | 3.3 | 50 |
| 48 | Evaluation of the Inhibitory Effect of Dihydropyridines on N-type Calcium Channel by Virtual Three-dimensional Pharmacophore Modeling. Arzneimittelforschung, 2009, 59, 283-288. | 0.4 | 5 |
| 49 | Oseltamivir (Tamiflu) Efflux Transport at the Blood-Brain Barrier via P-Clycoprotein. Drug Metabolism and Disposition, 2008, 36, 6-9. | 3.3 | 103 |
| 50 | What Kinds of Substrates Show P-Glycoprotein-Dependent Intestinal Absorption? Comparison of Verapamil with Vinblastine. Drug Metabolism and Pharmacokinetics, 2006, 21, 238-244. | 2.2 | 54 |
| 51 | Stereoselective and carrier-mediated transport of monocarboxylic acids across Caco-2 cells. Pharmaceutical Research, 1996, 13, 1828-1832. | 3.5 | 46 |